86 related articles for article (PubMed ID: 12436438)
1. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of interferon alpha and low-dose subcutaneous interleukin-2 in advanced renal cell carcinoma.
Piga A; Giordani P; Quattrone A; Giulioni M; De Signoribus G; Antognoli S; Cellerino R
Cancer Immunol Immunother; 1997 Aug; 44(6):348-51. PubMed ID: 9298938
[TBL] [Abstract][Full Text] [Related]
3. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.
Schwaab T; Schwarzer A; Wolf B; Crocenzi TS; Seigne JD; Crosby NA; Cole BF; Fisher JL; Uhlenhake JC; Mellinger D; Foster C; Szczepiorkowski ZM; Webber SM; Schned AR; Harris RD; Barth RJ; Heaney JA; Noelle RJ; Ernstoff MS
Clin Cancer Res; 2009 Aug; 15(15):4986-92. PubMed ID: 19622576
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer.
Pavone L; Andrulli S; Santi R; Majori M; Buzio C
Cancer Immunol Immunother; 2001 Apr; 50(2):82-6. PubMed ID: 11401029
[TBL] [Abstract][Full Text] [Related]
5. Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.
Passalacqua R; Buzio C; Buti S; Porta C; Labianca R; Pezzuolo D; Camisa R; Sabbatini R; Benecchi L; Messina C; Cengarle R; Vaglio A; Dalla Chiesa M; Tomasello G; Caminiti C
Cancer Immunol Immunother; 2010 Apr; 59(4):553-61. PubMed ID: 19779715
[TBL] [Abstract][Full Text] [Related]
6. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.
Yang JC; Sherry RM; Steinberg SM; Topalian SL; Schwartzentruber DJ; Hwu P; Seipp CA; Rogers-Freezer L; Morton KE; White DE; Liewehr DJ; Merino MJ; Rosenberg SA
J Clin Oncol; 2003 Aug; 21(16):3127-32. PubMed ID: 12915604
[TBL] [Abstract][Full Text] [Related]
7. Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial. Austrian Renal Cell Carcinoma Study Group.
Schmidinger M; Steger GG; Wenzel C; Locker GJ; Brodowicz T; Budinsky AC; Wiltschke C; Kramer G; Marberger M; Zielinski CC
Cancer Immunol Immunother; 2000 Sep; 49(7):395-400. PubMed ID: 10999466
[TBL] [Abstract][Full Text] [Related]
8. A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor.
Bex A; Mallo H; Kerst M; Haanen J; Horenblas S; de Gast GC
Cancer Immunol Immunother; 2005 Jul; 54(7):713-9. PubMed ID: 15627213
[TBL] [Abstract][Full Text] [Related]
9. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon.
Alpaugh RK; von Mehren M; Palazzo I; Atkins MB; Sparano JA; Schuchter L; Weiner LM; Dutcher JP
Med Oncol; 1998 Sep; 15(3):191-8. PubMed ID: 9819796
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma.
Rudman SM; Jameson MB; McKeage MJ; Savage P; Jodrell DI; Harries M; Acton G; Erlandsson F; Spicer JF
Clin Cancer Res; 2011 Apr; 17(7):1998-2005. PubMed ID: 21447719
[TBL] [Abstract][Full Text] [Related]
11. Histamine in immunotherapy of advanced melanoma: a pilot study.
Hellstrand K; Naredi P; Lindner P; Lundholm K; Rudenstam CM; Hermodsson S; Asztély M; Hafström L
Cancer Immunol Immunother; 1994 Dec; 39(6):416-9. PubMed ID: 8001030
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer.
Douillard JY; Bennouna J; Vavasseur F; Deporte-Fety R; Thomare P; Giacalone F; Meflah K
Cancer Immunol Immunother; 2000 Apr; 49(1):56-61. PubMed ID: 10782866
[TBL] [Abstract][Full Text] [Related]
13. Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2.
Stenehjem DD; Toole M; Merriman J; Parikh K; Daignault S; Scarlett S; Esper P; Skinner K; Udager A; Tantravahi SK; Gill D; Straubhar AM; Agarwal AM; Grossmann KF; Samlowski WE; Redman B; Agarwal N; Alva A
Cancer Immunol Immunother; 2016 Aug; 65(8):941-9. PubMed ID: 27277816
[TBL] [Abstract][Full Text] [Related]
14. Complete response of metastatic renal cell carcinoma to low-dose interferon-gamma treatment.
Otto F; Mackensen A; Mertelsmann R; Engelhardt R
Cancer Immunol Immunother; 1995 Feb; 40(2):115-8. PubMed ID: 7882381
[TBL] [Abstract][Full Text] [Related]
15. C-reactive Protein in Patients with Metastatic Clear Cell Renal Carcinoma: An Important Biomarker for Tumor-associated Inflammation.
Reichle A; Grassinger J; Bross K; Wilke J; Suedhoff T; Walter B; Wieland WF; Berand A; Andreesen R
Biomark Insights; 2007 Feb; 1():87-98. PubMed ID: 19690640
[TBL] [Abstract][Full Text] [Related]
16. The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma.
Pachella LA; Madsen LT; Dains JE
J Adv Pract Oncol; 2015; 6(3):212-21. PubMed ID: 26557408
[TBL] [Abstract][Full Text] [Related]
17. Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma.
Kapoor AK; Hotte SJ
Can Urol Assoc J; 2007 Jun; 1(2 Suppl):S28-33. PubMed ID: 18542782
[TBL] [Abstract][Full Text] [Related]
18.
Li Q; Zhang Z; Chen S; Huang Z; Wang M; Zhou M; Yu C; Wang X; Chen Y; Jiang D; Du D; Huang Y; Tu X; Chen Z; Zhao Y
Front Cardiovasc Med; 2021; 8():795675. PubMed ID: 35083300
[TBL] [Abstract][Full Text] [Related]
19. Effects of interleukin-2 in immunostimulation and immunosuppression.
Pol JG; Caudana P; Paillet J; Piaggio E; Kroemer G
J Exp Med; 2020 Jan; 217(1):. PubMed ID: 31611250
[TBL] [Abstract][Full Text] [Related]
20. Interferon-α versus interleukin-2 in Chinese patients with malignant melanoma: a randomized, controlled, trial.
Li S; Wu X; Chen P; Pei Y; Zheng K; Wang W; Qiu E; Zhang X
Anticancer Drugs; 2019 Apr; 30(4):402-409. PubMed ID: 30664008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
